| 期刊論文1. | Mahlich, Jörg、Yurtoglu, B. Burcin(2019)。Returns on Different Types of Investment in the Global Pharmaceutical Industry。MANAGE DECIS. ECON.,40(1),16-36。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 2. | Kim, Daniel J.(2018)。The Untimely Death of the On-Sale Bar to Patentability。U. BALT. L. REV.,47。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | Williams, John C.(2018)。Giving Meaning to "Otherwise Available to the Public": How Helsinn Perpetuates a Version of the On-Sale Bar to Patentability That Disproportionately Burdens Small Inventors。TEX. L. REV.,97。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 4. | Collier, Roger(2013)。Drug Patents: The Evergreening Problem。CMAJ,185(9)。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 5. | Wang, L.、Plump, A.、Ringel, M.(2014)。Racing to Define Pharmaceutical R&D External Innovation Models。DRUG DISCOV. TODAY,14。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 6. | Schuhmacher, A.、Germann, P. G.、Trill, H.(2013)。Models for Open Innovation in the Pharmaceutical Industry。DRUG DISCOV. TODAY,18。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 7. | Schuhmacher, Alexander、Gassmann, Oliver、Hinder, Markus(2016)。Changing R&D Models in Research-Based Pharmaceutical Companies。J. TRANSL. MED.,14(1)。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 8. | (2015)。聚焦新藥開發:智擎生技--創新新藥開發模式著力癌症治療領域。證券櫃檯雙月刊,176,30-31。 延伸查詢![new window](/gs32/images/newin.png) | 9. | 劉仁傑(20170800)。銷售阻卻新穎性從Medicines Company v. Hospira, Inc.談起。萬國法律,214,70-81。 延伸查詢![new window](/gs32/images/newin.png) | 10. | 王世仁(20171000)。美國專利關於銷售阻卻之最新實務。智慧財產權月刊,226,38-49。 延伸查詢![new window](/gs32/images/newin.png) | 11. | DiMasi, Joseph A.、Grabowski, Henry G.、Hansen, Ronald W.(2016)。Innovation in the pharmaceutical industry: New estimates of R&D costs。Journal of Health Economics,47,20-33。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 學位論文1. | 薛碧玲(2007)。製藥產業專業分工與新興經營模式探討(碩士論文)。國立臺灣大學。 延伸查詢![new window](/gs32/images/newin.png) | 2. | 張倪綸(2009)。生技製藥業新興經營模式--NRDO之架構探討(碩士論文)。世新大學。 延伸查詢![new window](/gs32/images/newin.png) | 圖書1. | 經濟部智慧財產局(2017)。專利審查基準。經濟部智慧財產局。 延伸查詢![new window](/gs32/images/newin.png) | 2. | FRIEDMAN, YALI(2014)。BUILDING BIOTECHNOLOGY: BIOTECHNOLOGY BUSINESS, REGULATIONS, PATENTS, LAW, POLICY AND SCIENCE。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | BUCKLEY, ANNA(2019)。THE LIFE SCIENTIFIC: INVENTORS。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 4. | JORDAN, JAMES F.(2014)。INNOVATION, COMMERCIALIZATION, AND START-UPS IN LIFE SCIENCES。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 5. | 楊智傑(2018)。美國專利法與重要判決。 延伸查詢![new window](/gs32/images/newin.png) | 其他1. | 公司簡介:經營模式,http://www.pharmaengine.com/zhhant/about-us/。 延伸查詢![new window](/gs32/images/newin.png) | 2. | 委託製造設計,https://www.tty.com.tw/ec99/rwd1181/Category.asp?Xcategory_id=11&category_id=23。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | 經銷,https://www.tty.com.tw/ec99/rwd1181/Category.asp?Xcategory_id=11&category_id=23。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 4. | 104年度年報,http://doc.twse.com.tw/pdf/2015_4105_20160624F04_20190222_071946.pdf。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 5. | 杜蕙蓉(20181224)。Trend Force:今年全球藥品市場規模預估為1.2兆美元,https://www.chinatimes.com/realtimenews/20181224002480-260410。 延伸查詢![new window](/gs32/images/newin.png) | 6. | Bultman, Matthew。'On Sale' Ruling Shows Need for Earlier Patent Applications,https://www.law360.com/articles/1120924。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | |